Delayed Ejaculation: What Could Be Causing It

How Common Is Delayed Ejaculation, and Who Gets It?

Delayed ejaculation is the least studied of the major male sexual dysfunctions, yet it is not rare. Population-based surveys place the overall prevalence between 1% and 4%, with the Global Online Sexuality Survey (GOSS) finding a self-reported rate of 3% across more than 12,000 respondents from 27 countries.

Age is a significant modifier. The Massachusetts Male Aging Study documented a near-threefold increase in ejaculatory difficulty between ages 40 and 70. After age 60, the prevalence may reach 12% to 18% when men with partial delay (markedly prolonged latency without complete anejaculation) are included. The ejaculatory reflex arc depends on intact peripheral nerves, coordinated sympathetic outflow, and adequate androgen signaling. Each of these declines with age.

DE also clusters in specific clinical populations. Men taking serotonergic antidepressants, those with poorly controlled diabetes, and men after radical pelvic surgery report rates many times the background level. Recognizing these high-risk groups helps clinicians ask the right screening questions early, rather than waiting for patients to volunteer a complaint they often find embarrassing.

Pharmacological Causes: Medications That Delay or Block Ejaculation

Drugs are the single most identifiable cause of DE in clinical practice. The mechanism typically involves serotonin-mediated inhibition of the spinal ejaculatory generator or alpha-adrenergic blockade of the seminal emission phase.

SSRIs and SNRIs. Serotonergic antidepressants are the most frequent offenders. A meta-analysis published in the Journal of Clinical Psychopharmacology found ejaculatory dysfunction in 25% to 73% of SSRI users, depending on the specific agent. Paroxetine carries the highest risk, while bupropion (a norepinephrine-dopamine reuptake inhibitor) carries the lowest, with rates near placebo. Sertraline and fluoxetine fall in between. The effect can appear within days of initiation and may persist for weeks to months after discontinuation, a phenomenon termed post-SSRI sexual dysfunction (PSSD).

Alpha-1 adrenergic blockers. Tamsulosin, prescribed widely for benign prostatic hyperplasia, causes retrograde or absent ejaculation in up to 18% of users by relaxing the bladder neck. Silodosin pushes that figure above 20%.

Other contributors. Antipsychotics (particularly risperidone through hyperprolactinemia), opioids, 5-alpha reductase inhibitors (finasteride, dutasteride), and thiazide diuretics have all been linked to ejaculatory delay in case series and pharmacovigilance databases. Chronic heavy alcohol use dampens central and peripheral nerve conduction enough to cause DE independently of any prescription medication.

The clinical takeaway is direct: a thorough medication reconciliation, including over-the-counter supplements and recreational substances, should precede any further workup.

Neurological and Surgical Causes

The ejaculatory reflex depends on an intact circuit: sensory afferents from the dorsal penile nerve travel to the spinal ejaculatory generator at T12 through L2 (emission) and S2 through S4 (expulsion), coordinated by supraspinal input from the medial preoptic area. Damage at any point disrupts the reflex.

Diabetic autonomic neuropathy. Diabetes is the most prevalent metabolic cause. A cross-sectional study in Diabetes Care found ejaculatory dysfunction in 32% to 37% of men with type 2 diabetes, correlated with HbA1c levels above 8% and duration of disease exceeding 10 years. The mechanism is distal small-fiber neuropathy affecting sympathetic fibers to the vas deferens and seminal vesicles.

Spinal cord injury (SCI). Ejaculatory capability after SCI depends on lesion level and completeness. Only about 9% of men with complete upper motor neuron lesions can ejaculate through intercourse alone, according to data from the National Spinal Cord Injury Statistical Center. Vibrostimulation and electroejaculation are standard interventions for fertility purposes in this population.

Multiple sclerosis. Demyelinating plaques in the thoracolumbar cord or brainstem interfere with both emission and expulsion phases. A European survey of men with MS reported ejaculatory problems in 50% of respondents.

Pelvic surgery. Retroperitoneal lymph node dissection (RPLND) for testicular cancer, radical prostatectomy, and abdominoperineal resection for rectal cancer all risk hypogastric plexus injury. Nerve-sparing surgical techniques have reduced but not eliminated DE and anejaculation in these contexts.

Hormonal and Endocrine Factors

Androgens support the ejaculatory threshold. Low testosterone reduces penile sensitivity, lowers arousal drive, and lengthens the intravaginal ejaculatory latency time (IELT).

The European Male Ageing Study (EMAS), which enrolled 3,369 men aged 40 to 79, found that total testosterone below 8 nmol/L (approximately 230 ng/dL) was significantly associated with ejaculatory difficulty after adjusting for age, BMI, and comorbidities. Free testosterone may be even more predictive, since SHBG rises with age and can mask a true tissue-level deficit.

Hyperprolactinemia deserves specific attention. Prolactin inhibits GnRH pulsatility and directly suppresses dopaminergic tone in the medial preoptic area. Drug-induced hyperprolactinemia (risperidone, metoclopramide) and prolactinomas both cause DE. The Endocrine Society guidelines recommend checking a serum prolactin level in any man presenting with DE of unclear etiology, particularly if libido is also reduced.

Thyroid dysfunction is a less recognized contributor. A prospective study in the Journal of Clinical Endocrinology and Metabolism showed that 50% of hypothyroid men had DE, and that thyroid hormone replacement normalized ejaculatory latency in the majority within 3 to 6 months. Screening TSH should be included in the baseline workup when hormonal causes are suspected.

Psychological and Behavioral Causes

Psychological DE is often situational. A man who can ejaculate through masturbation but not partnered intercourse almost certainly has a psychological or relational component. This pattern is the single most useful diagnostic clue.

Idiosyncratic masturbatory style. The concept was formalized by Dr. Michael Perelman, Clinical Professor of Psychiatry at Weill Cornell Medicine, who described it as "a conditioned pattern of high-frequency, high-pressure self-stimulation that partnered sex cannot replicate." Men in this category often report normal latency during adolescence with progressive prolongation as idiosyncratic technique becomes entrenched.

Performance anxiety and spectatoring. Cognitive distraction during intercourse, heightened self-monitoring, and fear of failure activate sympathetic tone that paradoxically inhibits the ejaculatory reflex. Performance anxiety is a contributor in an estimated 15% to 20% of psychogenic DE cases, per a review in the International Journal of Impotence Research.

Relationship factors. Partner attractiveness discord, unresolved conflict, lack of emotional intimacy, and mismatched sexual scripts all appear in the clinical literature as maintaining factors. These are best addressed through couple-based psychosexual therapy rather than individual pharmacotherapy.

Religious or cultural inhibition. Restrictive sexual upbringing, guilt, or the belief that sexual pleasure is inherently wrong can create an unconscious inhibitory brake. Cognitive-behavioral therapy (CBT) targeting these schemas has shown benefit in case series, though large controlled trials are lacking.

How Is Delayed Ejaculation Diagnosed?

Diagnosis rests on history. There is no blood test for DE, and the condition is defined clinically.

The DSM-5-TR criteria require a marked delay in, or marked infrequency or absence of, ejaculation on at least 75% to 100% of partnered sexual occasions, persisting for a minimum of approximately 6 months, and causing clinically significant distress. The condition is then subtyped as lifelong versus acquired and generalized versus situational. This subtyping is not academic: lifelong generalized DE suggests a neurobiological or anatomical substrate, while acquired situational DE points toward medication or psychological etiology.

A recommended workup includes:

• Sexual history: onset, circumstances, masturbatory pattern, partner variables, pornography use frequency
• Medication reconciliation: every prescription, OTC, supplement, and recreational substance
• Focused physical exam: genital sensation, bulbocavernosus reflex, prostate assessment
• Labs: total testosterone, free testosterone or SHBG, prolactin, TSH, fasting glucose or HbA1c

Dr. Chris McMahon, Director of the Australian Centre for Sexual Health, has noted: "The single biggest diagnostic error in DE is failure to take a proper drug history. Clinicians jump to the psychological explanation before excluding pharmacological causes that are completely reversible."

Urodynamic testing or somatosensory evoked potentials of the dorsal penile nerve are reserved for cases where a neurological lesion is suspected but not clinically obvious.

Treatment Options by Cause

Treatment for DE follows directly from the identified cause. No FDA-approved medication exists specifically for DE, so all pharmacotherapy is off-label.

Medication-induced DE. The first step is substitution. For SSRI-induced DE, switching to bupropion, mirtazapine, or vilazodone often restores ejaculatory function within 2 to 4 weeks. If the antidepressant cannot be changed, adjunctive strategies include adding bupropion 150 mg daily or cyproheptadine 4 to 8 mg taken 1 to 2 hours before intercourse. A randomized trial in the Journal of Clinical Psychiatry found that adjunctive bupropion improved ejaculatory function in 65% of participants versus 30% on placebo.

Hormonal DE. Testosterone replacement therapy (TRT) in men with confirmed hypogonadism and DE can improve ejaculatory latency. The Testosterone Trials (TTrials) demonstrated significant improvement in sexual activity scores, including orgasmic function, with testosterone gel versus placebo in men aged 65 and older with testosterone below 275 ng/dL. Prolactinomas are treated with cabergoline 0.25 to 1 mg twice weekly, which normalizes prolactin and typically restores ejaculation within 3 months. Hypothyroidism responds to levothyroxine titrated to a TSH target of 0.5 to 2.5 mIU/L.

Neurogenic DE. Options are more limited. Penile vibrostimulation at 80 to 100 Hz applied to the frenulum can trigger the ejaculatory reflex in men with partial neurological injury. Midodrine 5 to 15 mg, a peripheral alpha-1 agonist, has shown modest efficacy in spinal cord injury populations for inducing antegrade ejaculation. Imipramine 25 to 75 mg, which enhances sympathetic outflow, is another option in select cases.

Psychogenic DE. Cognitive-behavioral sex therapy remains the standard of care. Sensate focus, graduated masturbatory retraining (progressively reducing grip pressure and increasing use of lubricant to better approximate vaginal stimulation), and the "bridge technique" (incorporating manual or vibrator stimulation during intercourse until the point of ejaculatory inevitability) are the core behavioral interventions. A systematic review in Sexual Medicine Reviews found that combined behavioral and pharmacological approaches produced better outcomes than either alone.

Pharmacological options under investigation. Cabergoline 0.5 mg twice weekly has shown promise for idiopathic DE in small open-label studies by enhancing dopaminergic tone. Oxytocin nasal spray (24 IU before intercourse) is being explored for its role in facilitating the ejaculatory reflex, with preliminary results from a phase II study showing shorter IELT in a subset of men with acquired DE.

When Delayed Ejaculation Signals Something Serious

Most causes of DE are benign or medication-related. But certain patterns warrant urgent evaluation.

New-onset DE with perineal numbness, bowel or bladder incontinence, or progressive lower-extremity weakness suggests cauda equina compression. That requires emergency MRI and neurosurgical consultation. DE paired with galactorrhea, visual field cuts, or headaches raises concern for a pituitary macroadenoma. And abrupt-onset DE in a man with no medication changes and no psychological stressors warrants a full neurological exam, since early multiple sclerosis, spinal tumors, and posterior fossa lesions can present with isolated ejaculatory failure before other deficits become apparent.

A practical rule: if the DE is lifelong and situational, it is almost never dangerous. If it is acquired, generalized, and progressive, investigate aggressively.